Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095778 | 0.84 | CRHR1 (0.36) | PIKFYVERORCCRHR1CYP19A1MEN1 | |
| SCHEMBL4095782 | 0.79 | NR1H2 (0.34) | RORCCRHR1CYP19A1MEN1KMT2A | |
| SCHEMBL10666574 | 0.58 | CYP19A1 (0.45) | CYP3A4CYP3A5CYP19A1MEN1KMT2A | |
| SCHEMBL17594429 | 0.58 | PIM1 (0.40) | MEN1KMT2A | |
| SCHEMBL17591693 | 0.58 | PRKCQ (0.36) | CYP3A4CYP3A5 | |
| SCHEMBL22279162 | 0.57 | PDE2A (0.46) | PDE2AMEN1KMT2A | |
| SCHEMBL28670047 | 0.57 | PDE2A (0.46) | PDE2AMEN1KMT2A | |
| SCHEMBL25376121 | 0.56 | PDE2A (0.65) | PDE2AKMT2A | |
| SCHEMBL22279499 | 0.56 | PDE2A (0.65) | PDE2AKMT2A | |
| Trifluoroacetic Acid SCHEMBL30036865 | 0.56 | MEN1 (0.49) | CYP3A4CYP3A5CYP19A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | PDE2A 1101/4885ADORA2B 315/4885ADORA3 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.